Abstract
Left ventricular hypertrophy is considered to be a major cardiovascular risk factor in hemodialysis patients. Not only high blood pressure but also humoral factors such as angiotensin II and aldosterone are thought to contribute to the increase in left ventricular mass. We examined the effects of an angiotensin converting enzyme (ACE) inhibitor, imidapril, on left ventricular mass in patients with end-stage renal diseases on maintenance hemodialysis. Thirty patients on chronic hemodialysis were randomly divided into 2 groups of 15 patients each and given placebo or 2.5 mg imidapril once daily for 6 months. Before and after the 6-month period, left ventricular mass was evaluated by echocardiography, and circulating factors of the renin-angiotensin-aldosterone system were measured. Background characteristics such as age, gender ratio, causes of renal failure, duration of hemodialysis, body mass index and pre-dialysis blood pressure were comparable between the placebo and the imidapril groups. Systolic and diastolic blood pressures were not significantly changed in either group during the study period. In the imidapril group, serum ACE was reduced (12±1 to 5±2 U/l, p<0.01) and plasma renin activity was increased (3.3±0.8 to 8.1±3.2 ng/ml/h, p<0.01), but plasma angiotensin II and aldosterone were not significantly changed after 6 months (13±3 to 17±3 pg/ml and 365±125 to 312±132 pg/ml, respectively). On the other hand, left ventricular mass index was significantly decreased in the imidapril group (132±10 to 109±6 g/m2, p<0.05) but was unchanged in the placebo group (129±6 to 126±5 g/m2). These results suggest that an ACE inhibitor reduces left ventricular mass in hemodialysis patients by a mechanism that is independent of changes in blood pressure.
Similar content being viewed by others
Article PDF
References
Collins AJ, Kasiske B, Herzog C, et al: Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Outcomes: hospitalization and mortality. Am J Kidney Dis 2005; 45 ( 1 Suppl 1): S117–S138.
Japanese Society for Dialysis Therapy : An overview of dialysis treatment in Japan (as of Dec. 31, 2003). J Jpn Soc Dial Ther 2005; 38: 1–16.
Silberberg JS, Barre PE, Prichard SS, Sniderman AD : Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286–290.
Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE : Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277–1285.
Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS : Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4: 1486–1490.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE : Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379–1385.
Washio M, Okuda S, Mizoue T, et al: Risk factors for left ventricular hypertrophy in chronic hemodialysis patients. Clin Nephrol 1997; 47: 362–366.
Zoccali C, Mallamaci F, Tripepi G, et al: Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17: 1751–1758.
Assanelli D, Cannella G, Guerra UP, Cumintti S, Gaggiotti M : Effects of intravascular volume loading and unloading on atrial sizes and left ventricular function in dialyzed uremic man. Am J Noninvas Cardiol 1990; 4: 53–59.
Brewster UC, Setaro JF, Perazella MA : The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003; 326: 15–24.
Struthers AD, MacDonald TM : Review of aldosterone- and angiotensin II–induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663–670.
Diamond JA, Phillips RA : Hypertensive heart disease. Hypertens Res 2005; 28: 191–202.
Hayashi K, Nunami K, Kato J, et al: Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives. J Med Chem 1989; 32: 289–297.
Hosoya K, Ishimitsu T : Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. Cardiovasc Drug Rev 2002; 20: 93–110.
Conion PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ : Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996; 7: 2658–2663.
Zoccali C, Mallamaci F, Tripepi G, et al: Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17: 1751–1758.
Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.
Kasahara Y, Ashihara Y : Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981; 27: 1922–1925.
Ishimitsu T, Tsukada K, Ohta S, et al: Increased cardiovascular risk in long-term hemodialysis patients carrying deletion allele of ACE gene polymorphism. Am J Kidney Dis 2004; 44: 466–475.
Nitta K, Akiba T, Uchida K, et al: Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27: 47–52.
Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T : Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 1998; 31: 991–996.
Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB : Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881–886.
Lopez-Gomez JM, Verde E, Perez-Garcia R : Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Kidney Int Suppl 1998; 68: S92–S98.
Ozkahya M, Toz H, Qzerkan F, et al: Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002; 15: 655–660.
Gunal AI, Karaca I, Aygen B, Yavuzkir M, Dogukan A, Celiker H : Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study. J Int Med Res 2004; 32: 70–77.
Agarwal R, Lewis R, Davis JL, Becker B : Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 2001; 38: 1245–1250.
Lins RL, Elseviers M, Rogiers P, et al: Importance of volume factors in dialysis related hypertension. Clin Nephrol 1997; 48: 29–33.
Ventura JE, Sposito M : Volume sensitivity of blood pressure in end-stage renal disease. Nephrol Dial Transplant 1997; 12: 485–491.
London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL : Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786–2796.
Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G : Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002; 40: 728–736.
Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T : Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256–261.
Kanno Y, Kaneko K, Kaneko M, et al: Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004; 43: 380–386.
Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S : Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30: 659–664.
Salem MM : Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26: 461–468.
Mittal SK, Kowalski E, Trenkle J, et al: Prevalence of hypertension in a hemodialysis population. Clin Nephrol 1999; 51: 77–82.
Grekas D, Bamichas G, Bacharaki D, Goutzaridis N, Kasimatis E, Tourkantonis A : Hypertension in chronic hemodialysis patients: current view on pathophysiology and treatment. Clin Nephrol 2000; 53: 164–168.
Lakkis J, Lu WX, Weir MR : RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003; 5: 408–417.
Sato A, Saruta T : Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781–788.
Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD : Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999; 10 ( Suppl 12): S266–S272.
Delcayre C, Silvestre JS : Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999; 43: 7–12.
Davies E, MacKenzie SM : Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol 2003; 30: 437–445.
Takai S, Jin D, Sakaguchi M, Miyazaki M : Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res 2004; 27: 213–219.
Kubo M, Ochiai T, Kato J, Ishida R : Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). Jpn J Pharmacol 1991; 57: 517–526.
Saruta T, Arakawa K, Iimura O, et al: Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999; 22: 197–202.
Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD : Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002; 112: 110–114.
Hörl MP, Hörl WH : Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17: 288–294.
Akpolat T, Gumus T, Bedir A, Adam B : Acute effect of trandolapril on serum erythropoietin in uremic and hypertensive patients. J Nephrol 1998; 11: 94–97.
Erturk S, Ates K, Duman N, Karatan O, Erbay B, Ertug E : Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin-converting enzyme inhibitors. Nephrol Dial Transplant 1996; 11: 396–397.
Nakao K, Shirakura T, Azuma M, Maekawa T : Studies on erythropoietic action of angiotensin II. Blood 1967; 29: 754–760.
Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B : High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206–1210.
Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos DV : Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004; 4: 483–486.
Sikole A, Polenakovic M, Spiroska V, Polenakovic B, Klinkmann H, Scigalla P : Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif Organs 2002; 26: 98–102.
Nishikimi T, Futoo Y, Tamano K, et al: Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 2001; 37: 1201–1208.
Mallamaci F, Zoccali C, Tripepi G, et al: Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559–1566.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Matsumoto, N., Ishimitsu, T., Okamura, A. et al. Effects of Imidapril on Left Ventricular Mass in Chronic Hemodialysis Patients. Hypertens Res 29, 253–260 (2006). https://doi.org/10.1291/hypres.29.253
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.29.253
Keywords
This article is cited by
-
Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations
Journal of Human Hypertension (2023)
-
Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis
BMC Nephrology (2022)
-
Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15
BMC Nephrology (2018)
-
Management of hypertension for patients undergoing dialysis therapy
Renal Replacement Therapy (2016)
-
Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis
Current Cardiology Reports (2016)
